Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2022; 12(5): 165-170

Safety profile of remifentanil: A post-marketing study in Indonesia

Jarir At Thobari, Jonathan Hasian Haposan, Lukman Ade Chandra, Nastia Hidayati, Rianiasa Karunia Dewi, Rita Wahyu Purnamasari, Dyah Juliana Pudjiati.

Cited by 0 Articles

Remifentanil is a novel short-acting μ-opioid receptor agonist. Hence, it can be used as an alternative to fentanyl with additional short-acting potential. However, the safety profile of remifentanil in the Indonesian population through post-marketing surveillance has not been evaluated yet. Therefore, this study aims to evaluate the safety profiles of remifentanil in a multicenter pharmacovigilance study in Indonesia. There were 42 patients who used remifentanil during the 3 months of observation in six referral hospitals in Indonesia. It was found that 35 patients (83%) experienced at least one adverse event. There were 54 adverse events recorded during the observations, with hypotension and bradycardia being the most common adverse events, followed by nausea, respiratory depression, dizziness, shivering, warm sensation, and muscle rigidity. Based on the previous safety data, most of these adverse events were recognized as common adverse drug reactions of remifentanil. The expert panel meeting concluded that, from those adverse events, 98% were possibly related to remifentanil and only one adverse event was unlikely related. Based on this pharmacovigilance study, there are no additional safety concerns related to remifentanil as an analgesic and sedative drug indicated for patients on intubation, invasive mechanical ventilation, and noninvasive ventilation.

Key words: remifentanil, post-marketing surveillance, pharmacovigilance, sedative

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.